Raghav Chawla

Title: Raghav Chawla and His Patent on Autoimmune Hematological Disorders.

Introduction

Raghav Chawla is an inventor associated with Novartis AG and based in Bottmingen, Switzerland. His listed patent work concerns a treatment approach for autoimmune benign hematological disorders.

Latest Patents

Chawla is associated with 1 patent, titled “Method of Treating an Autoimmune Hematological Disorder.” The patent describes methods for treating conditions such as immune thrombocytopenia (ITP), cold agglutinin disease (CAD), warm autoimmune hemolytic anemia (wAIHA), and thrombotic thrombocytopenic purpura (TTP). The approach uses the Factor B inhibitor LNP023, also known as iptacopan, or a pharmaceutically acceptable salt, such as iptacopan hydrochloride.

Career Highlights

Chawla’s listed invention reflects research into complement pathway inhibition as a potential treatment strategy for autoimmune hematological conditions. His work is associated with Novartis AG, a pharmaceutical company.

Collaborations

Chawla’s listed coworkers include Thomas Holbro and Guido Junge. Their names indicate professional connections associated with the work, though the available information does not specify their individual contributions to the patent.

Conclusion

Raghav Chawla’s patent focuses on using iptacopan or a related salt to treat several autoimmune hematological disorders, highlighting his connection to pharmaceutical innovation at Novartis AG.